Status:
UNKNOWN
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identi...
Detailed Description
OBJECTIVES: * To use fixed lung tissue for histological evaluation and fresh tissue samples for molecular studies to study DNA, RNA, and protein abnormalities in lung preneoplastic and neoplastic les...
Eligibility Criteria
Inclusion
- All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung cancer.
Exclusion
- Inability to provide informed consent
- Minors
- Pregnant women
Key Trial Info
Start Date :
December 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2025
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT00898313
Start Date
December 1 2003
End Date
January 31 2025
Last Update
November 22 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37212
2
Veterans Affairs Medical Center - Nashville
Nashville, Tennessee, United States, 37212